QT time prolongation
Adverse drug events
Variants ✨For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Aldesleukin is used to treat metastatic (spread) kidney cancer when the kidney has had to be removed. It is infused intravenously or subcutaneously as a solution. Aldesleukin is a genetically modified variant of human interleukin-2 (IL-2), also known as T-cell growth factor. As part of the so-called cellular immune system, T cells also attack cancer cells and destroy them. Like the natural IL-2, aldesleukin increases the activity of T cells and thus has a growth-inhibiting and killing effect on tumor tissue. The exact mechanism has not been conclusively clarified. Unwanted effects can include flu-like symptoms, low blood pressure, anxiety, changes in the blood count (e.g. leukopenia), reduced kidney and lung function, shortness of breath or fluid retention (edema).
Since only aldesleukin was entered without any further substances, no pharmacokinetic interactions can be detected.
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability of aldesleukin is unknown. Protein binding [Pb] is not known. The metabolism does not take place via the common cytochromes.
|Serotonergic Effects a||0||Ø|
Rating: According to our knowledge, aldesleukin does not increase serotonergic activity.
Rating: According to our findings, aldesleukin does not increase anticholinergic activity.
QT time prolongation
We do not know of any QT-prolonging potential for aldesleukin.
General adverse effects
|Side effects||∑ frequency||ald|
|Elevated serum creatinine||33.0 %||33.0|
Anemia (29%): aldesleukin
Fever (29%): aldesleukin
Malaise (27%): aldesleukin
Peripheral edema (28%): aldesleukin
Tachycardia (23%): aldesleukin
Myocardial infarction: aldesleukin
Supraventricular tachycardia: aldesleukin
Pruritus (24%): aldesleukin
Asthenia (23%): aldesleukin
Somnolence (22%): aldesleukin
Loss of appetite (20%): aldesleukin
Capillary leak syndrome: aldesleukin
Based on your
No literature information available.